Baudax Bio, Inc. Common Stock
BXRX
BXRX was delisted on the 15th of November, 2023.
26 hedge funds and large institutions have $4.12M invested in Baudax Bio, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 7 closing their positions.
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
16% less funds holding
Funds holding: 31 → 26 (-5)
26% less capital invested
Capital invested by funds: $5.58M → $4.12M (-$1.46M)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$167K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$91.3K |
| 3 |
VF
Virtu Financial
New York
|
+$65.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$40K |
| 5 |
BlackRock
New York
|
+$12.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$225K |
| 2 |
Goldman Sachs
New York
|
-$115K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$21.7K |
| 4 |
PCM
Pinz Capital Management
New York
|
-$16K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$11.3K |
BXRX Hedge Fund Activity: Q3 2021 in Review
26 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Baudax Bio, Inc. Common Stock (BXRX) for Q3 2021, worth a combined $4.12M — down 26% from $5.58M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BXRX and 2 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 6 added.
The largest buyer was Millennium Management, adding an estimated $167K. The largest seller was Morgan Stanley, exiting entirely with an estimated $225K sold.
- 26 institutional investors held Baudax Bio, Inc. Common Stock (BXRX) as of Q3 2021, down from 31 in Q2 2021.
- Funds reported $4.12M of Baudax Bio, Inc. Common Stock stock for Q3 2021, down 26% quarter-over-quarter.
- 2 funds opened new Baudax Bio, Inc. Common Stock positions in Q3 2021 and 7 closed out, a net change of -5 holders.
- The largest Baudax Bio, Inc. Common Stock buyer in Q3 2021 was Millennium Management, an estimated $167K added.
- The largest Baudax Bio, Inc. Common Stock seller in Q3 2021 was Morgan Stanley, an estimated $225K sold.
Based on aggregated 13F filings for Q3 2021.